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Introduction: Corticosteroids are used empirically in influenza A (H1N1) treatment despite lack of clear evidence for
effective treatment. This study aims to assess the efficacy of corticosteroids treatment for H1N1 infection.
Methods: Systematic review and meta-analysis were used to estimate the efficacy of corticosteroids for the prevention
of mortality in H1N1 infection. Databases searched included MEDLINE, EMBASE, PubMed, Cochrane Central Register of
Controlled Clinical Trials and so on, and bibliographies of retrieved articles, from April 2009 to October 2014. We
included both cohort studies and case-control studies reported in English or Chinese that compared treatment effects
between corticosteroids and non-corticosteroids therapy in inpatients with H1N1 virus infection. Cohort studies
employed mortality as outcome, and case-control studies employed deaths as cases and survivors as controls; both
were assessed in this meta-analysis.
Results: In total twenty-three eligible studies were included. Both cohort studies (nine studies, n = 1,405) and
case-control studies (14 studies, n = 4,700) showed a similar trend toward increased mortality (cohort studies relative
risk was 1.85 with 95% confidence interval (CI) 1.46 to 2.33; case-control studies odds ratio was 4.22 with 95% CI 3.10 to
5.76). The results from both subgroup analyses and sensitive analyses were consistent with each other, showing that
steroid treatment is associated with mortality. However, considering the fact that corticosteroids were tend to be used
in sickest case-patients and heterogeneity was observed between studies, we cannot make a solid conclusion.
Conclusions: Available evidence did not support the use of corticosteroids as standard care for patients with severe
influenza. We conclude that further research is required.Introduction
Novel influenza A (H1N1) spread around the world in
spring 2009. Although influenza A (H1N1) infection has
a mild clinical course, the pandemic virus is capable of
leading to severe illness, requiring hospitalization. As an
example, the hospital admission rate for children with
2009 H1N1 influenza was twofold the rate for seasonal
influenza [1]. Additionally, approximately 9 to 31% of
hospitalized patients were admitted to an ICU, where
14 to 46% of patients died [2-5]. The disease caused
284,500 deaths globally [6,7]. Accordingly, there is an
increasing need for the development of an effective* Correspondence: bjcdcxm@126.com
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of severe cases.
In severe influenza infectious cases, cytokine dysregula-
tion was observed in patients [8] and corticosteroids had
been proven to be able to reduce systemic inflammation
by inhibition of proliferation and cytokine production
[8-11]. Previous meta-analyses of patients with acute long
injury and acute respiratory distress syndrome indicated
that prolonged glucocorticoid treatment is safe and is as-
sociated with significant reductions in markers of systemic
inflammation, multiple organ dysfunction score, duration
of mechanical ventilation, and ICU length of stay [11,12].
Moreover, Nie and colleagues’ study showed that the use
of corticosteroids was associated with improved mortality
in severe community-acquired pneumonia (CAP) [13].
According to the above accounts, corticosteroids were
used in 40 to 53% of patients with confirmed or probableThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and about 22% of inpatient children with H1N1 were
treated with corticosteroids [17]. Corticosteroids were
empirically used as a preferred or lifesaving treatment and
were observed in more than 50% of the severe patients,
including acute respiratory distress syndrome, during the
pandemic influenza in 2009 [4,18].
Although corticosteroids are widely used, the effect of
corticosteroids on pandemic A (H1N1) influenza patients
has not been studied adequately and, thus, is still contro-
versial. For example, in several studies a remarkable effect
was observed of early treatment with oseltamivir and
steroids for patients with severe pneumonia in preventing
disease progression [19-21]. Additionally, a number of
clinical case series and case reports have shown that pa-
tients with severe respiratory complications, pneumonia,
improved after the use of corticosteroids [22-24]. How-
ever, the USA Centers for Disease Control and Prevention
does not recommend the use of corticosteroids as a pri-
mary medicine for H1N1 infection, with the exception
that a reasonable dose is indicated for a specific reason;
for example, pulmonary obstruction or septic shock [25].
Moreover, World Health Organization guidelines for
Pharmacological Management of Pandemic Influenza A
(H1N1) 2009 and other InfluenzaViruses recommend that
systemic corticosteroids should not be administrated to
patients who have severe or progressive clinical illness
unless in some exceptional circumstances [26,27]. Severe
influenza treatment guidelines for Korea also indicate that
systemic corticosteroid administration should not be per-
formed for the treatment of severe influenza patients un-
less the therapeutic effect has already been proven [28].
None of the guidelines above recommend systematic cor-
ticosteroid use regularly with H1N1 infection. However,
lack of clinical evidence makes these recommendations or
guidelines unconvincing.
Until now, many studies involving the treatment of
severe H1N1 cases have been published, but the results
are inconsistent, which could be due to insufficient sam-
ple sizes, complicated clinical status, or study design. To
our knowledge, there has been no systematic literature
review evaluating the benefit of corticosteroids to severe
H1N1 infection. A principal resource for the optimal
clinical therapy of influenza A (H1N1) patients and di-
rections for future research are warranted.
We therefore conducted the present study to deter-
mine whether corticosteroids can treat severe H1N1
infection. To clarify the association of corticosteroids
with H1N1 mortality taking into account clinical sta-
tus and study design, we examined the associations in
larger, prospective cohort studies in global settings,
using existing literature, and assessed the effect of
corticosteroids treatment on mortality through meta-
analysis.Methods
Search strategy and selection criteria
We conducted a comprehensive literature search both for
English-language and Chinese-language articles examining
the effect of corticosteroid treatment in influenza A
(H1N1) published up until October 2014. Electronic data-
bases searched included: MEDLINE, EMBASE, PubMed,
Cochrane Central Register of Controlled Clinical Trials,
University of Saskatchewan Library System, China National
Knowledge infrastructure, Wan fang Data, and CBM disc.
We contacted article authors for further information or
clarification when necessary. No attempt was made to
include unpublished data. All searches were executed inde-
pendently by two skilled researchers. The search strategy
consisted of the terms (‘A (H1N1)’ or ‘A/H1N1’ or ‘influ-
enza’ or ‘viral pneumonitis’) and (‘corticosteroids’ or ‘ste-
roids’) as medical subject-heading key words. In addition,
the reference lists of retrieved original articles and of rele-
vant systematic reviews were manually checked. No ethics
board approval was deemed necessary for a meta-analysis
of previously published studies.
Eligibility criteria
Because there was no randomized trial available, we
included both cohort studies and case–control stud-
ies. We included cohort studies fulfilling the following
selection criteria: enrolled patients had confirmed,
probable, or suspected influenza A (H1N1); all of the
subjects were inpatient, or admitted to the ICU, or
critically ill; corticosteroid treatment was compared
with noncorticosteroid treatment within the cases;
and data about hospital mortality were accessible. For
case–control studies, the inclusion criteria were that:
enrolled patients had confirmed, or had probable or
were suspected of having influenza A (H1N1); all of
the subjects were inpatient, or admitted to the ICU,
or critically ill; deaths were cases and survivors were
controls; and the numbers of patients who received
or did not receive steroid treatment were presented
in two groups. There were no restrictions on studies
with respect to age groups.
Studies were excluded if they: included seasonal influ-
enza infection cases; were in vitro tests, animal experi-
ments, case studies, case series, and review or letter
articles; and targeted special crowds, such as pregnant
women and patients with HIV infections.
Additionally, confirmed influenza A (H1N1) cases
were defined as an acute respiratory illness with la-
boratory confirmation by real-time PCR or viral cul-
ture. Corticosteroid treatment was defined as: systemic
corticosteroid use; and nonstandardized corticosteroid
use, which was decided by the attending physician
and was regardless of type, dosage, and frequency of
administration.
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All full articles were reviewed for the selection and
exclusion of publications with predefined inclusion cri-
teria by two researchers independently. We also con-
tacted the corresponding author of 12 studies by email
to ask for additional details. However, only three authors
responded. For both case–control and cohort studies,
the following information was collected for each study:
first author, year of publication, country or origin, study
design, inclusion/exclusion criteria, participant demogra-
phics, sample size, antiviral treatment, and corticosteroid
dose, formulation, and duration. For case–control studies,
we collected information about the numbers of patients
treated with steroids in each group. With regard to cohort
studies, information about the number of patients who
died in each group and other clinical outcomes were col-
lected. Disagreements were resolved by consensus.
Qualitative assessment
The Newcastle-Ottawa Scale scoring system was used to
assess the methodology and quality of both cohort stud-
ies and case–control studies [29]. The Newcastle-Ottawa
Scale assigns a maximum score of 4 for selection, 2 for
comparability, and 3 for exposure (case–control studies)
or outcome (cohort studies). Hence, a score of 9 is the
highest possible and reflects the best quality. Two inves-
tigators independently assessed the risk of bias of
each study. The detailed evaluation criteria are shown
in Additional file 1. Inter-rater agreement was assessed
using Cohen's kappa statistics and disagreements were
resolved by consensus.
Statistical analysis
We calculated the relative risk for death within cohort
studies, while the odds ratio (OR) was used for case–
control studies. Heterogeneity of treatment effects
among studies was assessed by examining forest plots,
and statistically using Cochran Q and I2 statistics. If
significant heterogeneity was seen (P <0.1 and I2 > 30), a
random-effects model was selected; otherwise, a fixed-
effects model was used. Two-sided P <0.05 was consid-
ered to be statistically significant. If a significant hetero-
geneity was identified, subgroup analyses were carried
out. Studies were categorized by sample size, by whether
the subjects from two groups are comparable in terms of
age and antiviral treatment, and by whether the studies in-
cluded probable and suspected A (H1N1) cases. Sensitivity
analysis excluded studies one by one to investigate the
heterogeneity. Potential publication bias was assessed by
Begg and Mazumdar’s rank correlation test [30] and by
observing funnel plots. We attempted to summarize the
corticosteroids’ effect on other clinical outcomes by de-
scribing the results from studies. All statistical analysis
was performed using the Comprehensive Meta-AnalysisV2 software (Biostat Inc., Englewood, NJ, USA) and
Review Manager V5 software (Nordic Cochrane Center,
Copenhagen, Denmark).
Role of the funding source
The sponsor of this study had no role in the study de-
sign, data collection, data analysis, data interpretation,
writing of the report, or decision to submit the paper for
publication. The corresponding authors had full access
to all data in the study and had final responsibility for
the decision to submit the paper for publication.
Results
Study characteristics
Of the 2,321 references screened, 23 studies were in-
cluded in the final analysis (Figure 1). Fourteen studies
were case–control studies [15,31-43], and nine studies
were cohort studies [44-52]. In total, 6,105 subjects were
analyzed, with 4,700 subjects in case–control studies and
1,405 subjects in cohort studies. Among these studies,
seven studies were conducted in China [36,39,41-44,50],
three in Spain [33,45,49], three in India [31,35,46], two
in Korea [18,28], two in Argentina [15,40], and one study
each was conducted in Mexico [37], Turkey [38], Saudi
Arabia [48], France [51], and Finland [52], while the
remaining study was multicenter and conducted in several
countries (European Society of Intensive Care Medicine)
[47]. The characteristics of the included studies are sum-
marized in Table 1. Participants in all studies were in-
patients. Eighteen studies only included patients in the ICU
or critically ill cases [15,32-36,38-40,42,44,46-52], and three
studies included children [35,36,40]. There was only one
study that did not mention antiviral treatment use in pa-
tients [44]. Corticosteroid treatment varied among these
studies, with most using methylprednisolone or hydrocorti-
sone; doses varied from 80 to 320 mg daily. However, there
were still several studies which did not describe the taper-
ing doses in detail, or the precise duration of treat-
ment. Two Spanish studies showed that corticosteroid
administrations were not standardized and were de-
cided by the attending physician without detailed data
[33,49]. Another six studies did not provide any detailed
information about dose, duration, and treatment mode
[34,40,42-44,52].
Qualitative assessment
There was consensus between reviewers with regard to
the validity assessments (Cohen’s kappa was 58%). The
overall quality of the included studies was moderate and
the analyses are presented in Figure 2 and Figure 3.
Most studies were retrospective and observational studies,
and the most common bias was lack of comparability in
terms of age or antiviral therapy between study groups. In
addition, some studies did not provide detailed data with
Figure 1 Study identification, inclusion and exclusion.
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obtained either from the registration systems or by
reviewing hospital records, and the response rate was not
reported. They were therefore judged as high risk in this
respect. Only a few studies demonstrated that they ex-
cluded steroid-use cases for underlining diseases, while
other studies did not mention this at all.
Primary outcome – mortality
Case–control studies
Significant heterogeneity was found for case–control
studies (I2 = 49%). The random-effects model was there-
fore used and the combined OR was 4.22 (95% CI = 3.10
to 5.76) (Figure 2).
Subgroup analysis was conducted to investigate the
heterogeneity, and the results are shown in Additional
file 2. The plots show that the sample size of studies, as
well as comparability in terms of age and antiviral treat-
ment, did not significantly influence the final mortality
outcome. The heterogeneity was not statistically signifi-
cant, after studies were categorized according to whether
they enrolled suspected or probable cases, and the
pooled OR was 5.05 (95% CI = 4.14 to 6.15) in studies
that only enrolled confirmed cases, while the pooled OR
was not statistical significant in the other group [15,39,40]
(OR = 1.50, 95% CI = 0.87 to 2.58).
In sensitivity analysis, we found that heterogeneity was
not examined after excluding Rios and colleagues’ study
[15], and the result suggested that high mortality was
associated with steroid treatment (OR = 4.97, 95% CI =
4.08 to 6.04).
Cohort studies
With regard to the nine cohort studies, we noted that
there was no significant heterogeneity between studies(I2 = 10%), so a fixed-effects model was used and the
nine cohort studies had a relative risk of 1.85 (95% CI =
1.46 to 2.33), which suggested mortality was higher in
patients who were given steroids (Figure 3). Subgroup
analyses, as shown in Additional file 3, revealed that the
relative risk was higher in studies of poor quality than
that of the good quality studies. However, the difference
was not statistically significant. Besides, the inclusion of
probable and suspected cases did not significantly change
the result, consistently showing steroid treatment was a
risk factor of mortality.
Other clinical outcomes
Zhang and colleagues’ study showed that corticosteroid
treatment has a better therapeutic effect when compared
with nonsteroid treatment [44]. Similarly, another Chinese
study indicated that patients in steroid treatment groups
have a shorter duration of fever and a shorter duration of
inflammation [50]. In addition, Martin-Loeches and col-
leagues’ study showed that patients who received early
corticosteroid therapy had hospital-acquired pneumonia
more frequently than patients who did not [47].
Regarding length of hospitalization, Kudo and colleagues’
study demonstrated an increased length of hospital stay in
patients with corticosteroid treatment when compared
with the controls, despite no significant difference being
found [53]. Also, Linko and colleagues study showed that
the length of ICU and hospital stay was significantly lon-
ger in the patients treated with corticosteroids [52].
Regarding the duration of mechanical ventilation, Diaz
and colleagues displayed that there was no difference
between the corticosteroid and noncorticosteroid groups
[49]. By contrast, Linko and colleagues’ study showed
that patients treated with corticosteroids have signi-
ficantly longer durations of mechanical ventilation [52].
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Antiviral Corticosteroid doses and duration
Rios, 2011 [15] Argentina Case–control Confirmed influenza A (H1N1)
and ARDS and mechanical
ventilation and ICU
178 44 98/55.0 Treatment with oseltamivir was
given to 98% of patients, with
60% receiving 300 mg/day. The
frequency of use and doses
were similar in both survivors
and nonsurvivors
Corticosteroids were prescribed
in 36% of patients for septic
shock as 300 mg/day
hydrocortisone
Chawla, 2013 [31] India Case–control Confirmed influenza A (H1N1)
cases and inpatient
77 40.88 33/42.9 No statistical difference
between two groups
Steroids were administered for
an average duration of 10.61 days
Hong, 2013 [32] South Korea Case–control Confirmed influenza A (H1N1)
cases and critical illnesses and
adult




Jose, 2013 [33] Spain Case–control Confirmed influenza A (H1N1)
cases and requiring ICU
admission and age ≥15 years
1,120 72 365/32.6 Not comparable between two
groups (more dead patients
use antiviral after 48 hours
after hospital admission)
Corticosteroid use was not
standardized and was decided
by the attending physician
Jung, 2011 [34] South Korea Case–control Confirmed influenza A (H1N1)
cases and critical illnesses and
requiring ICU admission and
age ≥15 years
221 57 103/46.6 All patients received antiviral
treatment, and the duration
from symptom onset to initial
antiviral treatment did not
differ
No mentioned
Kinikar, 2012 [35] India Case–control Confirmed influenza A (H1N1)
cases and inpatient or admitted
to the ICU and children
92 2.5 49/53.0 All patients received antiviral
treatment
Short course of corticosteroids
was administered to 21 children
Li, 2012 [36] China Case–control Confirmed influenza A (H1N1)
case sand critical illnesses and
children and inpatient
1,137 4 390/34.3 Not comparable between two
groups (more survival patients
use antiviral within 48 hours
of onset of illness)
Median duration of corticosteroids
treatment was 6 days
Perez-Padilla,
2009 [37]
Mexico Case–control Confirmed influenza A (H1N1)
cases and inpatient and
pneumonia
18 38 9/50.0 None of the patients were
given oseltamivir during the
first 48 hours after the onset
of symptoms
Corticosteroids were administered
at the discretion of the attending
physicians. Hydrocortisone at a
dose of 300 mg/day or




Turkey Case–control Confirmed influenza A (H1N1)
cases and requiring ICU
admission and pneumonia
20 36 10/50.0 None of them had taken
oseltamivir within 48 hours.
Overall, patients received
oseltamivir therapy at a
dosage of 75 mg twice a day
for 5 days
Not mentioned
Sun, 2010 [39] China Case–control Confirmed influenza A (H1N1)
cases and ICU
18 37 8/44.4 Oseltamivir 150 mg, twice daily Methylprednisolone: 3 to 5 days,
1 to 2 mg/kg; or hydrocortisone
300 mg/day
Torres, 2012 [40] Argentina Case–control Confirmed influenza A (H1N1)
and pediatric ICU
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Xi, 2010 [41] China Case–control Confirmed influenza A (H1N1)
cases and adult and inpatient
155 43 65/41.9 No statistical difference between
two groups
There were 33.5% patients treated
with systemic corticosteroids,
daily dose of corticosteroids
ranged from methylprednisolone
12 to 320 mg (or equivalent dose),
with a median dose of 80 mg
Yu, 2011 [42] China Case–control Confirmed influenza A (H1N1)
cases and critical illnesses and
inpatient
128 28.5 51/39.8 Not comparable between two
groups (more survival patients
used oseltamivir)
Not mentioned
Zhang, 2013 [43] China Case–control Confirmed influenza A (H1N1)
cases and severe or critical ill
and ≥14 years old
2,151 34.0 1069/49.7 95.3% of patients received
oseltamivir treatment
No mentioned
Zhang, 2011 [44] China Cohort Confirmed influenza A (H1N1)
cases and critical illnesses and
inpatient
146 44.21 57/39.0 Not mentioned High dose, high dose plus low
dose, and low lose
Viasus, 2011 [45] Spain Cohort Confirmed influenza A (H1N1)
cases and pneumonia and
inpatient
197 N/A 106/53.8 No statistical difference exists
between steroid group and
nonsteroid group
Seventeen (48%) patients received
Corticosteroids at a daily dose
above 300 mg hydrocortisone
or its equivalent
Patel, 2013 [46] India Cohort Confirmed influenza A
(H1N1) cases and ICU
63 34 22/35.0 Patients without pneumonia
were treated with oseltamivir,
75 mg p.o. twice daily, and
those with pneumonia were
treated with 150 mg p.o. twice
daily. In pediatric patients, an
appropriate weight-based
dose of oseltamivir was used
Methylprednisolone 40 mg i.v.
every 8 hours for first week
followed by every 12 hours for
second week and every 24 hours
for third week were used for




Europe Cohort Confirmed influenza A (H1N1)
and ICU
220 43 113/51.4 All patients received antiviral
therapy
Systemic corticosteroid use was
considered when dosages
equivalent to >24 mg/day
methylprednisone or > 30 mg/day
prednisone were given at ICU
admission
Mady, 2012 [48] Saudi Arabia Cohort Confirmed influenza A (H1N1)
cases and admitted to the ICU
and respiratory failure
86 40.8 22/28.0 Not comparable between two
groups (more dead patients use
antiviral after 48 hours after
hospital admission)
Methylprednisolone 1 mg/kg
per day for early phase ARDS,
continued for 7 days
Diaz, 2012 [49] Spain Cohort Confirmed influenza A (H1N1)
cases and acute respiratory
failure requiring ICU admission
and pneumonia
372 43.4 167/44.9 All patients received antiviral
therapy
Corticosteroids administered
were not standardized and
were decided by the attending
physician
Chen, 2010 [50] China Cohort Confirmed influenza A (H1N1)
cases and critical illnesses
12 33.5 6/50.0 All patients received oseltamivir Methylprednisolone 80 mg/day
(five cases) or 320 mg/day
(one case), median duration of
corticosteroid treatment was
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Brun-Buisson,
2011 [51]
France Cohort Confirmed influenza A (H1N1)
cases and requiring ICU
admission and ARDS
208 45.5 105/50.5 Four patients did not receive
antiviral therapy. Time from
ARI to antiviral therapy use
has no significant difference
between two groups
Steroid therapy was initiated at
a median daily dose equivalent
to 270 (IQR, 200 to 400) mg
hydrocortisone, and patients
were treated for a median
duration of 11 (IQR, 6 to 20) days
Linko, 2011 [52] Finland Cohort Confirmed influenza A (H1N1)
cases and admitted to the ICU
132 47 · 8 47/35.6 Oseltamivir was given to 96%
patients. No statistical difference
between two groups
Not mentioned
Kudo, 2012 [53] Japan Cohort Confirmed influenza A (H1N1)
cases and respiratory disorders
and inpatient
89 80 cases < 15 years 44/49.4 All subjects were treated with
antiviral agents, either
oseltamivir or zanamivir
The dosage of corticosteroids was
equivalent to methylprednisolone
1.0 to 1.5 mg/body weight
(kg)/time, two to four times/day,
in subjects under 15 years of age,
and 40 to 80 mg/time, two to
four times/day in those over
15 years of age. The median
number of days from symptom
onset to initiation of administration
of systemic corticosteroids was
2.1 (range, 1 to 6). The median
duration of systemic corticosteroid
treatment was 5.2 days (range,
2 to 9)









Figure 2 Effect of corticosteroids on influenza A (H1N1) cases from case–control studies. Diamond, overall estimate from the meta-analysis;
square, point estimate of the result of each study; horizontal line that runs through the square and the width of the diamond represents the CI. Red
dot, high risk of bias; green dot, low risk of bias; A to I, see Additional file 1. CI, confidence interval; M-H, Mantel-Haenszel.
Zhang et al. Critical Care  (2015) 19:46 Page 8 of 11Since the mean difference was not provided in Linko
and colleagues’ study, we were not able to calculate the
pooled effect. Viasus and colleagues’ study found that
patients who received corticosteroid treatment needed
significantly more time to reach clinical stability [45].
Publication bias
In the present meta-analysis, no publication bias was
observed between case–control studies and cohort stud-
ies using the Begg and Mazumdar rank correction test
(P = 0.8 and P = 0.91). However, the funnel plots pro-
vided evidence of publication bias for both types of studies
(Additional file 4).Figure 3 Effect of corticosteroids on influenza A (H1N1) cases from co
square, point estimate of the result of each study; horizontal line that runs
Red dot, high risk of bias; green dot, low risk of bias; A to I, see AdditionalDiscussion
During the 2009 influenza pandemic, the debate over
whether to use corticosteroid treatment in severe influ-
enza H1N1-infected patients resurfaced and was disputed
by clinicians [26]. According to our review, corticosteroid
administration is likely to increase mortality in patients
with influenza A (H1N1), and the trend is consistent re-
gardless of the quality as well as the sample size of studies.
Apart from the studies included in this meta-analysis,
there are many studies that refer to the steroids used and
the outcomes, and most of them reported that cortico-
steroids have negative effects or no effect on H1N1 treat-
ment. For example, Balaganesakumar and colleagueshort studies. Diamond, overall estimate from the meta-analysis;
through the square and the width of the diamond represents the CI.
file 1. CI, confidence interval; M-H, Mantel-Haenszel.
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risk of poor patient outcomes [54]. Other reports showed
that patients who received corticosteroids were more
likely to develop secondary bacterial pneumonia [47,55] or
were associated with an increased risk of developing crit-
ical illness, with ICU admission, or had more prolonged
ICU stays [17,55-57]. The possible explanation for the
negative effectiveness of corticosteroids might be that
corticosteroids could inhibit immune reactions. However,
immune systems should be activated in order to eliminate
the virus [58]. Altered immune reactions thus might lead
to prolonged virus viremia [59] and delay viral clearance
[60], and ultimately increase the risk of mortality.
Indeed, there are several studies that reveal the posi-
tive role of corticosteroids, but most of them used ani-
mal models [61] or case series that lacked a control
group [22,24]. Therefore, it might be difficult to draw
conclusions that corticosteroids have any advantages
over nonuse corticosteroids. Besides, although previous
studies suggested that the clinical outcome in patients
hospitalized with CAP was improved by systemic corti-
costeroids [13], researchers pointed out that these stud-
ies included predominantly CAP cases with bacterial
infection and were given appropriate antibiotic therapy;
thus, the encouraging results cannot be popularized to
all CAP, especially those with viral infection [8].
Nevertheless, our study has some limitations. Firstly,
heterogeneity cannot be ignored in our research. Since it
is impossible to conduct a clinical trial on critically ill
patients, only observational studies were retrieved and
enrolled in our meta-analysis. While observational studies
are potentially susceptible to bias and induce between-
study heterogeneity due to clinical diversity, we cannot
draw a robust conclusion. Second, as noticed by clinicians,
critical patients were more likely to be given steroids than
patients with mild cases [52,62]; the severity of illness
should therefore be taken into account. Among the 23
included research papers, 17 studies conducted further
multivariable analysis to adjust for potential confounding
factors and to determine whether corticosteroid treat-
ment is a predictor of mortality. Among these, 14 studies
showed that corticosteroid treatment was not an inde-
pendent risk factor for mortality, although there was a
trend towards greater mortality, while the remaining three
studies suggested that corticosteroid treatment could in-
crease the mortality risk independently. Through the real-
ity of the abovementioned factors, we cannot draw a solid
conclusion about the effectiveness of corticosteroids in
treating severe influenza A (H1N1) cases. Besides, it is dif-
ficult to evaluate fairly the effect according to the dose,
time given, and baseline of steroid use, because steroid
usage was varied by the attending physician and very few
studies gave detailed information about it. Hence, further
clinical studies – especially those with a comparative andrigorous design regarding the timing, the formulation of
corticosteroids, the dosage, the duration, and the length of
tapering – as well as randomized studies may help to clar-
ify this issue.
Conclusions
Our findings suggest that corticosteroids have no benefi-
cial effects in treating patients with influenza A (H1N1).
Our results provide evidence regarding the therapeutic
strategy for both World Health Organization and USA
Centers for Disease Control and Prevention guidelines.
A stronger study design and data replication are necessary
moving forward.
Key messages
 Our findings suggest that corticosteroids have no
beneficial effects in treating patients with influenza
A (H1N1).
 Available evidence did not support the use of
corticosteroids as standard care for patients with
severe influenza.
 Our paper will be of interest to medical researchers
and physicians who fight against influenza A
(H1N1) in the first line.
Additional files
Additional file 1: Presents the Newcastle-Ottawa Scale for quality
assessment.
Additional file 2: Presents subgroup analyses for case–control studies.
Additional file 3: Presents subgroup analyses for cohort studies.
Additional file 4: Presents funnel plots for case–control studies and
cohort studies.
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